Carcinogenesis, Vol 18, 383-389, Copyright © 1997 by Oxford University Press
D Ziebarth, B Spiegelhalder and H Bartsch
Micro-organisms commonly present in human saliva and three DSM strains
(Helicobacter pylori, Campylobacter jejuni and Neisseria cinerea), which
can be isolated from the human gastro-intestinal tract, were assayed in
vitro for their capacity to catalyse N-nitrosation of a series of medicinal
drugs and other compounds. Following incubation at pH 7.2 in the presence
of nitrate (or nitrite) for up to 24 (48) h, the yield of N-nitroso
compounds (NOC) was quantified by HPLC equipped with a post-column
derivatization device, allowing the sensitive detection of acid-labile and
acid-stable NOC. Eleven out of the 23 test compounds underwent
bacteria-catalysed nitrosation by salivary bacteria, the yield of the
respective nitrosation products varying 800-fold. 4-
(Methylamino)antipyrine exhibited the highest rate of nitrosation, followed
by dichlofenac > metamizole > piperazine > five other drugs,
whilst L-proline and L-thioproline had the lowest nitrosation rate. Ten
drugs including aminophenazone, cimetidine and nicotine, did not inhibit
bacterial growth, allowing transitory nitrite to be formed, but no
N-nitroso derivatives were detected. Three drugs inhibited the
proliferation of bacteria and neither nitrite nor any NOC were formed.
Using metamizole as an easily nitrosatable precursor, two strains,
Campylobacter jejuni and Helicobacter pylori, were shown to catalyse
nitrosation in the presence of nitrite at pH 7.2. As compared to Neisseria
cinerea used as a nitrosation-proficient control strain, H. pylori was
30-100 times less effective, whilst C. jejuni had intermediary activity.
The results of our sensitive nitrosation assay further confirm that
bacteria isolated from human sources, possessing nitrate reductase and/or
nitrosating enzymes such as cytochrome cd1- nitrite reductase (Calmels et
al., Carcinogenesis, 17, 533-536, 1996), can contribute to intragastric
nitrosamine formation in the anacidic stomach when nitrosatable precursors
from exogenous and endogenous sources are present.
ARTICLES
N-nitrosation of medicinal drugs catalysed by bacteria from human saliva and gastro-intestinal tract, including Helicobacter pylori
Max-Delbruck-Centrum, Berlin-Buch, Germany.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  I. Stepanov, S. G. Carmella, A. Briggs, L. Hertsgaard, B. Lindgren, D. Hatsukami, and S. S. Hecht Presence of the Carcinogen N'-Nitrosonornicotine in the Urine of Some Users of Oral Nicotine Replacement Therapy Products Cancer Res., November 1, 2009; 69(21): 8236 - 8240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Dicksved, M. Lindberg, M. Rosenquist, H. Enroth, J. K. Jansson, and L. Engstrand Molecular characterization of the stomach microbiota in patients with gastric cancer and in controls J. Med. Microbiol., April 1, 2009; 58(4): 509 - 516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Jung, T. M. Heinze, J. Deck, R. Strakosha, and J. B. Sutherland Transformation of N-Phenylpiperazine by Mixed Cultures from a Municipal Wastewater Treatment Plant Appl. Envir. Microbiol., October 1, 2008; 74(19): 6147 - 6150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G M Naylor, T Gotoda, M Dixon, T Shimoda, L Gatta, R Owen, D Tompkins, and A Axon Why does Japan have a high incidence of gastric cancer? Comparison of gastritis between UK and Japanese patients Gut, November 1, 2006; 55(11): 1545 - 1552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Adjei, T. M. Heinze, J. Deck, J. P. Freeman, A. J. Williams, and J. B. Sutherland Transformation of the Antibacterial Agent Norfloxacin by Environmental Mycobacteria Appl. Envir. Microbiol., September 1, 2006; 72(9): 5790 - 5793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Nair, H. Bartsch, and J. Nair Alert for an epidemic of oral cancer due to use of the betel quid substitutes gutkha and pan masala: a review of agents and causative mechanisms Mutagenesis, July 1, 2004; 19(4): 251 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Sinues, A. Fanlo, M. L. Bernal, M. Val, and E. Mayayo Omeprazole treatment: genotoxicity biomarkers, and potential to induce CYP1A2 activity in humans Human and Experimental Toxicology, March 1, 2004; 23(3): 107 - 113. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Z Stolzenberg-Solomon, K. W Dodd, M. J Blaser, J. Virtamo, P. R Taylor, and D. Albanes Tooth loss, pancreatic cancer, and Helicobacter pylori Am. J. Clinical Nutrition, July 1, 2003; 78(1): 176 - 181. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Marais, G. L. Mendz, S. L. Hazell, and F. Megraud Metabolism and Genetics of Helicobacter pylori: the Genome Era Microbiol. Mol. Biol. Rev., September 1, 1999; 63(3): 642 - 674. [Abstract] [Full Text] [PDF]
|
|